Alveolar nitric oxide *versus* measures of peripheral airway dysfunction in

severe asthma

Ilonka H. van Veen, Peter J. Sterk, Robert Schot, Stefanie A. Gauw, Klaus F. Rabe and

Elisabeth H. Bel

Dept. of Pulmonology
Leiden University Medical Center
The Netherlands

Corresponding author:
H.P.A.A. van Veen
Dept. of Pulmonology C3P-18
Leiden University Medical Center
Albinusdreef 2
2333 ZA, Leiden
The Netherlands
Tel: 00-31-71-5262950
Fax: 00-31-71-5266927
e-mail: h.p.a.a.van_veen@lumc.nl

Copyright 2006 by the European Respiratory Society.
Abstract

Alveolar nitric oxide (NO) is a measure of peripheral airway inflammation in asthma, potentially associated with disease severity. The relationship between alveolar NO and physiological tests of peripheral airway (dys)function has not been investigated. We hypothesised that peripheral airway inflammation and dysfunction are interrelated and associated with asthma severity.

Alveolar NO was compared between 17 patients with mild-to-moderate and 14 patients with severe asthma and related to total lung capacity (TLC), residual volume (RV/TLC), thoracic gas volume (FRC), slope of the single breath nitrogen washout curve (dN₂), closing capacity (CC/TLC) and fall in forced vital capacity during methacholine challenge (ΔFVCpc20). In patients with severe asthma strong correlations were found between alveolar NO and RV/TLC%pred, FRC%pred, dN₂, and CC/TLC. Patients with oral steroid-dependent asthma had higher alveolar NO levels (2.7 ppb) compared to the other patients with severe (0.6 ppb) and mild-to-moderate asthma (0.3 ppb). We conclude that alveolar NO is closely related to parameters of peripheral airway dysfunction in patients with severe asthma, and that oral steroid-dependent asthmatics have more peripheral airway disease than non-steroid-dependent asthmatics. This suggests that patients on chronic oral steroid treatment have more extensive disease and require additional anti-inflammatory treatment to better target the peripheral airways.
Introduction

The need for understanding refractory asthma becomes increasingly important since milder forms of the disease can now be well treated(1). Little is known about the reason why some patients exhibit unstable disease despite maximum therapy with inhaled or even oral steroids. One of the proposed mechanisms is the presence of inflammation in the peripheral airways which seems to be an important feature of patients with asthma, in particular of those with severe disease(2-6). Inflammation of the distal lung in asthma has been demonstrated in post mortem tissue in patients who died from an asthmatic attack(2;6), in resected lung tissue(3) and in transbronchial biopsies(4;5) and has been suggested to contribute to instability of the disease(5;7), therapy resistance(8) and excessive airway narrowing(9).

Recent studies have shown that alveolar nitric oxide (NO) is a potentially useful measurement for investigating the role of peripheral airway inflammation in asthma. Alveolar NO has been related to bronchoalveolar lavage eosinophil cathionic protein (ECP) levels in children(10) and to bronchoalveolar lavage eosinophil counts in adults(11). However, the relationship between alveolar nitric oxide as a measure of peripheral airway inflammation and physiologic tests of peripheral airway function has never been investigated.

Over the years, several physiological tests have been proposed to estimate the degree of peripheral airway function(7;9;12-15). A few studies have investigated the relationship between some of these tests and pathological evidence of peripheral airway inflammation. The slope of the nitrogen single breath washout test appeared to be related to the degree of small airway inflammation in lung tissue from smokers in one study(12), whilst another study showed that thoracic gas volume (FRC) and total lung capacity (TLC) were related to the number of eosinophils in transbronchial biopsies from patients with severe asthma(14).
In the present study we hypothesized that the degree of peripheral airway inflammation and
dysfunction are interrelated and positively associated with asthma severity. Therefore, we
compared alveolar NO between patients with mild-to-moderate and severe asthma, and
assessed the relationship between alveolar NO and six different physiological tests proposed
to reflect peripheral airway function: total lung capacity (TLC), residual volume (RV/TLC),
thoracic gas volume (FRC), the slope of the nitrogen washout test (dN₂), closing capacity
(CC/TLC), and the fall in forced vital capacity during methacholine challenge (ΔFVCₚc₂₀).

Methods
Subjects

Seventeen patients with mild-to-moderate asthma and 14 with severe asthma, according to previously published criteria(16), were recruited. All had a pulmonologist diagnosis of asthma and documented reversible airway obstruction(16). All patients were on inhaled steroid treatment. Patients with mild-to-moderate asthma were using \( \leq 800 \, \mu g \) beclometasone/day (or equivalent) with beta-agonists prn. Patients with severe asthma were all using high doses of inhaled corticosteroids (\( \geq 1600 \, \mu g \) beclometasone/day, or \( \geq 800 \, \mu g \) in case of chronic oral steroid use) plus long-acting beta-agonists, and occasionally additional leukotriene-antagonists (n=5). They had at least one exacerbation in the previous year requiring steroid treatment and/or were on chronic oral steroids. Current smokers and patients with a smoking history of more than 5 pack years were excluded from participation. The patients visited the lung function laboratory on 3 different days within one month. At day 1 alveolar NO measurements were performed before spirometry. Methacholine provocation test was performed on the second day. At day 3 lung volume measurements and the single breath nitrogen washout test were performed. The study was approved by the Ethics Committee of the Leiden University Medical Centre and all patients gave written informed consent.

Spirometry

FEV\(_1\) and IVC before and after bronchodilation (inhalation of 400 \( \mu g \) salbutamol) were measured. Reversibility was expressed as postbronchodilator FEV\(_1\) – prebronchodilator FEV\(_1\) / FEV\(_1\) predicted. Predicted values were obtained from Quanjer and co-workers and used for analysis(17).

Lung volumes
Lung volumes were measured (TLC, RV, FRC) pre-bronchodilation using body plethysmography according to standard methods\(^{(17)}\). Predicted values were obtained from Quanjer and co-workers\(^{(17)}\).

*Methacholine provocation test; assessment of \(\Delta FVC_{pc20}\)*

Methacholine challenge testing was performed using a standardized tidal breathing method \(^{(18)}\) modified according to Gibbons\(^{(9)}\). Patients received doubling doses of methacholine starting with a dose of 0.03 mg/ml. After each dose FEV\(_1\) and FVC were measured until FEV\(_1\) dropped \(\geq\) 20% compared to baseline (PC\(_{20}\)). The percentage fall in FVC at the PC\(_{20}\) concentration of methacholine (\(\Delta FVC_{pc20}\)) was then calculated using log-linear interpolation.

*Single breath Nitrogen washout test*

Nitrogen single breath washout tests were performed in order to assess ventilation inhomogeneity. The slope of the nitrogen alveolar plateau (dN\(_2\)), closing volume and closing capacity were calculated as previously described\(^{(7)}\).

*Exhaled NO and calculation of alveolar NO levels*

Exhaled NO (FeNO) was measured according to criteria of the American Thoracic Society\(^{(19)}\) at three different flow rates: 100, 175 and 370 ml/sec, with a chemoluminescence analyser (Sievers, NOA 270B), mouth pressure 8-10 cmH\(_2\)O\(^{(20)}\). At each flow rate at least three technically adequate measurements were performed. FeNO was measured at a plateau between 5 and 8 seconds after reaching the correct exhalation flow rate or, in case of insufficient exhalation time, during a plateau phase of at least three seconds\(^{(19)}\). The average value was then taken for analysis. Measurements were excluded if an adequate NO plateau could not be reached, or if NO levels were below the detection limit. The contributions of the
bronchi (bronchial NO flux) and the alveoli (alveolar NO concentration) to exhaled NO were derived from regression analysis, with NO output as dependent and exhalation flow rate as independent factor(20). The slope and intercept of the regression line are approximates of alveolar NO concentration and bronchial NO flux, respectively.

Analysis

Unpaired Student's *t*-test, non-parametric tests (Mann Whitney, Kruskal Wallis) and chi-square analysis were used to analyse differences between groups. Spearman correlation coefficients were used to assess relationships between different parameters. All analyses were performed using the Statistical Package of the Social Sciences (SPSS-12.0). P-values less than 0.05 were considered statistically significant.
Results

1. Patient Characteristics

See table 1. Patients with mild-to-moderate and severe asthma did not differ with respect to age and gender. Patients with severe asthma were using higher doses inhaled steroids as defined in the inclusion criteria, 43% of them were using oral corticosteroids (median (range) dose: 7.5 (2.5-15) mg.). Post-bronchodilator FEV₁ was higher in the patients with mild-to-moderate asthma and these patients had more reversibility in FEV₁.

2. Alveolar NO measurements

Adequate alveolar NO measurements could be performed in 16 patients with mild-to-moderate and 10 patients with severe asthma. One patient with mild and 4 patients with severe asthma were excluded because of the lack of an adequate NO plateau or because of a NO concentration below the detection limit at one or more flow rates (this was the case in 1 patient with mild and 2 with severe asthma). The linearity of the relationship between NO output and exhalation flow rate was satisfactory (mean R = 0.82). In 5 patients with mild-to-moderate asthma and 2 with severe asthma a negative association between NO-output and exhalation flow rate was found, resulting in negative alveolar NO concentrations.

3. Comparison between mild-to-moderate and severe asthma

a. Alveolar NO

Alveolar NO was not different between the patients with severe and mild-to-moderate asthma (Table 2, Figure 1). However, the subgroup of oral steroid-
dependent patients had significantly higher alveolar NO levels (median (range) 2.7 (2.0-9.6) ppb) than the non-steroid-dependent patients with severe asthma (0.6 (-2.8-8.3) ppb, p=0.05) or those with mild-to-moderate asthma (0.3 (-1.4-3.9) ppb, p=0.01) (Table 3). Exhaled NO at 100 ml/sec and bronchial NO flux were similar in patients with mild-to-moderate and (steroid-dependent) severe asthma (p=0.93 and 0.82 resp.)

b. Functional parameters

In the total group of patients with severe asthma only dN2 and ∆FVCpc20 were higher than in the patients with mild-to-moderate asthma (Table 2, Figure 2). Surprisingly, TLC%pred was higher in the patients with mild-to-moderate asthma as compared to severe asthma.

In the subgroup of patients with severe steroid-dependent asthma dN2, RV/TLC%pred, and CC/TLC were significantly higher than in the other patients with severe asthma (Table 3).

4. Relationship between alveolar NO and functional parameters

In the total group of patients with mild-to-moderate and severe asthma there were no correlations between alveolar NO and functional parameters except for dN2 (r=0.45, p=0.02, Figure 3). However, within the group of patients with severe asthma, alveolar NO correlated strongly and positively with all functional parameters of airway dysfunction: FRC%pred. (ρ=0.84, p=0.002), RV/TLC%pred (ρ=0.83, p=0.003), dN2 (ρ=0.72; p=0.02), and CC/TLC (ρ=0.86; p=0.002), except for TLC%pred (p=0.26) and ∆FVCpc20 (p=0.82) (Figure 4). In patients with mild-to-moderate asthma there was no correlation between alveolar NO and any of the functional parameters.
### Table 1. Patient characteristics in mild-to moderate and severe asthma.

<table>
<thead>
<tr>
<th></th>
<th>Mild-to-moderate asthma (n=17)</th>
<th>Severe asthma (n=14)</th>
<th>p-value</th>
</tr>
</thead>
<tbody>
<tr>
<td>Age (yrs)</td>
<td>35.7 (10.9)</td>
<td>43.4 (16.6)</td>
<td>0.13</td>
</tr>
<tr>
<td>Female sex (%)</td>
<td>59</td>
<td>57</td>
<td>0.93</td>
</tr>
<tr>
<td>Inhaled steroid (µg)</td>
<td>445 (185)</td>
<td>1155 (455)</td>
<td>0.000</td>
</tr>
<tr>
<td>Oral steroid (n)</td>
<td>0</td>
<td>6</td>
<td>0.004</td>
</tr>
<tr>
<td>PbFEV₁ (%pred)</td>
<td>102 (80-120)</td>
<td>89 (40-109)</td>
<td>0.04</td>
</tr>
<tr>
<td>Reversibility (%)</td>
<td>11.0 (1-29.2)</td>
<td>7.2 (0-22.5)</td>
<td>0.003</td>
</tr>
</tbody>
</table>

Values in mean (sd), *median (range), Pb=post-bronchodilator

### Table 2. Outcome parameters in mild-to moderate and severe asthma.

<table>
<thead>
<tr>
<th></th>
<th>Mild-to-moderate asthma (n=17)</th>
<th>Severe asthma (n=14)</th>
<th>p-value</th>
</tr>
</thead>
<tbody>
<tr>
<td>Alv. NO (ppb)</td>
<td>0.3 (-1.4-3.9)</td>
<td>1.9 (-2.8-9.6)</td>
<td>0.11</td>
</tr>
<tr>
<td>Br. NO (nl/s)</td>
<td>1.9 (0.8-4.3)</td>
<td>2.1 (0.1-5.8)</td>
<td>0.94</td>
</tr>
<tr>
<td>FRC (%pred)</td>
<td>118.8 (22.8)</td>
<td>101.8 (25.2)</td>
<td>0.06</td>
</tr>
<tr>
<td>TLC (%pred)</td>
<td>104.0 (11.6)</td>
<td>94.9 (8.0)</td>
<td>0.02</td>
</tr>
<tr>
<td>RV/TLC (%pred)</td>
<td>105.5 (25.9)</td>
<td>113.4 (18.2)</td>
<td>0.35</td>
</tr>
<tr>
<td>dN₂ (%/L)</td>
<td>0.8 (0.3-2.1)</td>
<td>1.6 (0.5-9.1)</td>
<td>0.02</td>
</tr>
<tr>
<td>CC/TLC (L)</td>
<td>39.7 (6.3)</td>
<td>46.8 (12.0)</td>
<td>0.06</td>
</tr>
<tr>
<td>ΔFVCpc20 (%)</td>
<td>10.8 (4.0-19.1)</td>
<td>13.5 (11.4-21.8)</td>
<td>0.03</td>
</tr>
</tbody>
</table>

Values in mean (sd), *median (range). Alveolar NO and Bronchial NO were measured in 16 patients with mild-to-moderate and 10 patients with severe asthma.
Table 3. Comparison of steroid dependent and non-steroid-dependent severe asthma.

<table>
<thead>
<tr>
<th></th>
<th>Severe Asthma oral steroids (n=6)</th>
<th>Severe Asthma no oral steroids (n=8)</th>
<th>p-value</th>
</tr>
</thead>
<tbody>
<tr>
<td>Alv. NO (ppb)</td>
<td>2.7 (2.0-9.6)</td>
<td>0.6 (-2.8-8.3)</td>
<td>0.05</td>
</tr>
<tr>
<td>Br. NO (nl/s)</td>
<td>1.8 (0.1-2.4)</td>
<td>2.1 (0.6-5.9)</td>
<td>0.67</td>
</tr>
<tr>
<td>FeNO_{100} (ppb)</td>
<td>20.7 (5.4-33.4)</td>
<td>19.8 (6.6-57.8)</td>
<td>0.67</td>
</tr>
<tr>
<td>FRC (%pred)</td>
<td>113.5 (89-141)</td>
<td>84.5 (61-131)</td>
<td>0.07</td>
</tr>
<tr>
<td>TLC (%pred)</td>
<td>93.5 (90-104)</td>
<td>96 (81-111)</td>
<td>1.0</td>
</tr>
<tr>
<td>RV/TLC (%pred)</td>
<td>123.5 (113-162)</td>
<td>103.5 (86-117)</td>
<td>0.004</td>
</tr>
<tr>
<td>dN\textsubscript{2} (%) /L</td>
<td>3.2 (1.1-9.1)</td>
<td>1.0 (0.5-2.2)</td>
<td>0.02</td>
</tr>
<tr>
<td>CC/TLC (%)</td>
<td>53.8 (44-70)</td>
<td>40.3 (29-53)</td>
<td>0.01</td>
</tr>
<tr>
<td>ΔFVC\textsubscript{PC20} (%)</td>
<td>12.9 (11.4-14.2)</td>
<td>14.6 (11.7-21.8)</td>
<td>0.26</td>
</tr>
</tbody>
</table>

Values in median (range). Alveolar NO and Bronchial NO were measured in 4 patients with and 6 patients without oral steroids.
Discussion

This study shows that alveolar NO is closely related to parameters of peripheral airway dysfunction in patients with severe asthma, but not in patients with mild-to-moderate asthma. Within the group of patients with severe asthma, those patients on continuous oral corticosteroid treatment had more peripheral airway inflammation and dysfunction than patients with severe asthma on inhaled corticosteroids alone, and patients with mild-to-moderate asthma. This suggests that peripheral airway inflammation is not related to asthma severity per se, although it seems to be an important characteristic of patients with steroid-dependent asthma.

In this study alveolar NO levels could be adequately measured in the majority of adults with asthma of varying severity, including severe asthma. As compared to other investigators who measured alveolar NO in adults with mild-to-moderate persistent asthma(21), severe asthma(11) and in children with mild(22), and refractory asthma(10), we obtained alveolar NO levels in a lower range (3-4 fold lower). This could be due to differences between patient characteristics, and/or differences in the technical aspects of the measurements, such as the use of higher flow rates to calculate alveolar NO in our study. The alveolar NO levels in our study were comparable to those of Lehtimaki, who used the same flow rates and was the first to measure alveolar NO levels in patients with asthma (23;24)

The comparison of alveolar NO levels between patients with mild-to-moderate asthma and severe asthma did not reveal a significant difference after initial analysis, which was surprising. In studies by other groups higher levels of alveolar NO were found in symptomatic children versus asymptomatic children with asthma(22), in patients with nocturnal asthma as compared to non-nocturnal asthma(23) and in
patients with severe versus mild-to-moderate asthma (11). The explanation for a lack of
significant difference in alveolar NO levels between patients with mild-to-moderate
and severe asthma in our study could be the large variability of alveolar NO-levels
amongst the patients with severe asthma. Apparently, these patients are
heterogeneous with respect to their degree of peripheral airway inflammation. When
considering the subgroup of patients with oral corticosteroid dependency much
higher alveolar NO levels were observed as compared to patients on inhaled
corticosteroids alone. The same holds for the parameters of peripheral airway
dysfunction. This is remarkable because one could expect that systemic treatment in
these patients would reduce the amount of peripheral airway inflammation and
dysfunction. Apparently, there is extensive peripheral airway disease in these
patients, which is not fully controlled by such a high level of anti-inflammatory
treatment. The heterogeneity of patients with severe asthma is thus an important
factor to be taken into account when studying disease mechanisms in these patients.

Alveolar NO and parameters of peripheral airway dysfunction showed strong and positive
correlations in the patients with severe asthma, but not in patients with mild asthma or in the
group as a whole (except for dN2). Probably, most of these parameters are not sensitive
enough to detect small changes in patients with milder disease of the peripheral airways. The
strong association between alveolar NO and almost all parameters of airway dysfunction
suggests that these two entities coexist and are possibly causally related. This fits in with the
recently observed relationship between FeNO and dN2 in patients with mild asthma (25) and in
smokers (26). Additional anti-inflammatory treatment specifically targeting the peripheral
airways might improve peripheral airway function and thereby overall lung function in
patients with severe asthma.
$\Delta FVC_{pc20}$ was not related to alveolar NO, although there was a significant difference in this parameter between mild-moderate and severe asthma. $\Delta FVC_{pc20}$ is a measurement that is performed after stimulation of the bronchi with the bronchoconstrictor agent methacholine. It is assumed that the more FVC decreases during bronchoconstriction the more closure of peripheral airways has occurred. The major difference with the other tests of peripheral airway dysfunction is that $\Delta FVC_{pc20}$ is measured in constricted airways, thereby mimicking an acute asthma attack. The discrepancy between $\Delta FVC_{pc20}$ and the other tests suggest that airway dysfunction at rest does not predict the dynamics of peripheral airway dysfunction during acute bronchoconstriction. This is compatible with mathematical models of airway function(27). Thus, peripheral airway disease at rest and peripheral airway dysfunction during bronchoconstriction are two distinct conditions that do not necessarily coexist within the same subject, and may be reflected by different tests of peripheral airways disease.

The present study may have some limitations. First, the power of the study might not have been enough to detect statistical significant differences between the groups of patients with mild-to-moderate and severe asthma. In retrospect, based on the present study data, the power was enough to detect a difference in mean alveolar NO of 5.0 ppb. In order to detect a difference of 2 ppb, 57 patients would have been needed in each group. Secondly, the calculation of alveolar NO is based on a mathematical two-compartment model, which has its limitations. In seven patients negative alveolar NO values were calculated, while the measurements were technically adequately performed. The choice of expiratory flows rates of 100, 175 and 370 ml/sec hampered an adequate estimation of the NO concentration – expiratory flow rate curve in these patients. To improve this we would have needed
measurements at extra flow rates, especially in the higher range, however this is difficult to achieve in patients with flow limitation. This indicates that the model used (with these expiratory flows) was not completely sufficient for all patients. Until now, however, there are no better tests for the assessment of peripheral airway inflammation in patients with asthma except for invasive tests such as transbronchial biopsies.

The results of this study have implications for the assessment and treatment of patients with severe asthma. Similar to the fractional concentration of NO in exhaled air, alveolar NO could be successfully used to guide therapy in asthma(28;29). This study shows that patients with similar fractional levels of exhaled NO can have different alveolar NO levels. Thus, alveolar NO provides additive information for the clinician. The elevated levels of alveolar NO in patients already on continuous oral corticosteroids, suggest that the inflammatory process in the peripheral airways is extensive and still relatively undertreated despite the administration of systemic treatment. Measurement of alveolar NO levels might therefore be used in clinical practice to adjust anti-inflammatory treatment, for example by the addition of fine-particle inhaled corticosteroids or novel systemic anti-inflammatory therapies. In this way it might be possible to improve disease severity, avoid excessive airway narrowing and prevent a poor prognosis.

In conclusion, alveolar NO is an easy to perform, non-invasive test to estimate the degree of peripheral airway inflammation. It provides important information on peripheral airway disease and can be used in addition to functional tests such as TLC, RV/TLC, FRC, dN₂, CC/TLC or ΔFVC_{pc20}. Patients with severe asthma are heterogeneous with respect to the degree of peripheral airway disease. Those patients who are dependent on oral corticosteroids seem to have the most prominent
signs of peripheral airway inflammation and dysfunction. This suggests that these patients might require additional or alternative anti-inflammatory treatment to better target the peripheral airways. Alveolar NO might become an important new tool for the clinician to detect insufficiencies of asthma treatment, to tailor asthma therapies in individual patients, and to improve asthma control.


